Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

TLR5 drives metabolic dysfunction-associated steatohepatitis through lipid- and flagellin-induced hepatocyte injury signaling.

Created on 19 Nov 2026

Authors

Wenhao Li, Niannian Wang, Dania El Abyad, Seray Anak, Raju Kumar, Iris Ginés, Upkar Gill, Gillian Hood, James Brindley, Charles Mein, James Boot, Una Rose Wilcox, Neil Dufton, Robert Goldin, Tania Roskams, John Loy, Kalpana Devalia, Humza Malik, Adam Goralcyzk, Maria Jimenez-Ramos, Timothy J Kendall, Jonathan A Fallowfield, Maria Ines Castanho Martins, Krista Rombouts, Michele Vacca, Olivier Govaere, William Alazawi

Published in

Science advances. Volume 12. Issue 47. Pages eaef9541. Nov 20, 2026. Epub Nov 18, 2026.

Abstract

Liver fibrosis is a strong predictor of clinical outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Fibrosis is a consequence of persistent liver cell injury and inflammation in which Toll-like receptors (TLRs) play a key initiating role. Here, we test the hypothesis that TLR5 is involved in the development of MASH and fibrosis using a combination of clinical data from multiple independent patient cohorts, single-cell liver transcriptomics, and human in vitro and ex vivo models. Hepatic TLR5 expression, but not TLR2 or TLR4, is associated with liver fibrosis and mortality. Plasma levels of TLR5's cognate ligand flagellin are increased in MASH with advanced fibrosis and fall with liver disease improvement. Mechanistically, we identify two parallel TLR5-mediated routes to hepatocyte injury: one elicited by flagellin and the other indirectly by lipid injury. Furthermore, hepatocyte TLR5 inhibition abrogates paracrine activation of hepatic stellate cells to suppress collagen production. This is also seen ex vivo in patient-derived precision-cut liver slices where TLR5 inhibition significantly reduces lipid-induced collagen deposition. These findings reveal a new role for TLR5 signaling, specifically in the development of advanced MASH fibrosis and may offer a novel disease-specific therapeutic approach.

PMID:
43050520
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement